The FDA approved the type 2 diabetes drug tirzepatide for use in chronic weight management Wednesday, making official the use of a medicine already widely prescribed off-label for weight loss.
A prominent Senate panel on Wednesday unanimously passed a new package of health policy reforms that would rein in certain PBM practices and ensure Medicare patients aren't paying more than insurers do for medications.